Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. - Wikidata - wikimedia - TriplyDB

Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.

Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q37389632

about

Immune Thrombocytopenic Purpura During Maintenance Phase of Acute Lymphoblastic Leukemia: A Rare Coexistence Requiring a High Degree of Suspicion, a Case Report and Review of the Literature.Patterns of Radiation-Associated Lymphopenia in Children with Cancer Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia.Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia.Redefining clinical risk classification in children with precursor B cell acute lymphoblastic leukemia using pre-treatment absolute lymphocyte count.Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.

P2860

Q33422337-7C8A1311-6697-4024-B87A-D5CDCDADCE7A Q36663654-7377495F-C8EE-4269-863B-36BC6F0AE9C6 Q41257297-E5AD8E09-661A-46BF-BAC8-A2CED0C5C2BD Q48156506-4078CAAA-B17C-4E6E-B04F-B980D72A0F85 Q50438156-230CCBCB-D9F9-49D4-8713-9183AE460733 Q50922836-F87463ED-DBC0-4154-9017-BF4313C4C676

P2860

Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q37389632

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prognostic impact of absolute ...... acute lymphoblastic leukemia.

@en

Prognostic impact of absolute ...... acute lymphoblastic leukemia.

@nl

type

label

Prognostic impact of absolute ...... acute lymphoblastic leukemia.

@en

Prognostic impact of absolute ...... acute lymphoblastic leukemia.

@nl

prefLabel

Prognostic impact of absolute ...... acute lymphoblastic leukemia.

@en

Prognostic impact of absolute ...... acute lymphoblastic leukemia.

@nl

P1433

Q37389632-41CAC99B-F4FB-4350-A034-A03D46423360

P1476

Q37389632-EFA32B71-9FED-43AC-93A1-15BC8B28DEB9

P2093

Q37389632-077A6344-78AA-4E9C-9D88-B3C079D21F6F

Q37389632-62AF5A22-A930-4774-AD2D-79236747DDA6

Q37389632-7013CEDA-D26A-4AED-9238-1D10213E82EC

Q37389632-7EA99D2F-2F8E-4FA5-98AF-0BE2B5669CFE

Q37389632-9EC6588F-FCF2-4980-82F2-C698B315AA0D

Q37389632-AF580086-FFF7-4D0C-83B6-DC9508192A59

Q37389632-B0AB06CC-26AB-4FA0-80D4-3BA4FAEEC931

Q37389632-D71AF93C-1D6F-4205-84E3-D1BD38697925

Q37389632-DCD8E53D-CC96-4DE3-BF35-155D4E38D28C

Q37389632-DF4BDD15-548D-4935-9D52-E08B4964BD29

P2860

Q37389632-207797F9-68FF-4B47-9325-778D0EB187CD

Q37389632-239E2A80-14B2-4FEF-A975-46B9679480E9

Q37389632-5AEBD547-2446-47F7-AE18-09FBEAF10BDC

Q37389632-5C2B84ED-9C38-4206-82ED-E3122981CF93

Q37389632-5DEFD9D2-F804-4782-AC86-0E6B5702C9B3

Q37389632-6FF90EB4-B836-4C4F-AB5A-26BCAD381DA3

Q37389632-8CC9AFB5-3F36-468A-AAC3-D2B4CC8E1AF9

Q37389632-9D7D0F51-5468-4F80-9C14-3952B44BA025

Q37389632-9FC32FD1-BE8C-4F95-B2E1-46C358DA4301

Q37389632-A1FA67F7-E696-4CE0-9AD6-C83733063F53

P304

Q37389632-A9ED9816-01C2-46D4-BF7C-1B4696B49E9A

P31

Q37389632-3E17D4FC-8FE2-4332-A807-CADC08A5A423

P356

Q37389632-6FCC80A6-2EB3-41BF-86EB-D838449187BC

P407

Q37389632-0BB4996E-E876-4958-9A21-D64AF33947DD

P433

Q37389632-34F49207-FA9B-4ABE-9BAF-D2F142B6C781

P478

Q37389632-B093CC53-9DC0-41C2-9408-3CC9DBE869E8

P50

Q37389632-4BFF1406-02D5-4357-9FFC-E4E3203073FE

Q37389632-B3A27FF4-91BE-4C0F-BE1D-26AB2AAD4122

P577

Q37389632-61208C82-0A6A-45CF-B687-811CEC0BB458

P5875

Q37389632-0D036B9D-92F6-42D7-9496-FC1BCC01EECC

P698

Q37389632-7196BB3F-D680-49BE-A1AA-975E8CBE055D

P921

Q37389632-55D880FA-25A6-4E67-A7BF-7C33307A5CDE

Q37389632-A779D308-16BD-4475-8423-73C82821EE9C

P932

Q37389632-08AE901C-0F0C-4B84-A91F-CA1C13C83EE1

P356

P1433

P1476

Prognostic impact of absolute ...... d acute lymphoblastic leukemia

@en

P2093

Ching-Hon Pui

http://www.w3.org/2001/XMLSchema#string

Dario Campana

http://www.w3.org/2001/XMLSchema#string

Hiroto Inaba

http://www.w3.org/2001/XMLSchema#string

John T Sandlund

http://www.w3.org/2001/XMLSchema#string

Mary V Relling

http://www.w3.org/2001/XMLSchema#string

Patrick Campbell

http://www.w3.org/2001/XMLSchema#string

Raul C Ribeiro

http://www.w3.org/2001/XMLSchema#string

Scott C Howard

http://www.w3.org/2001/XMLSchema#string

Sima Jeha

http://www.w3.org/2001/XMLSchema#string

Yinmei Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Treating childhood acute lymphoblastic leukemia without cranial irradiation

Nonparametric Estimation from Incomplete Observations

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia.

Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia

Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies.

P304

2061-2066

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28026

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey Rubnitz

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235777849

http://www.w3.org/2001/XMLSchema#string

P698

23456849

http://www.w3.org/2001/XMLSchema#string

P921

P932

3862024

http://www.w3.org/2001/XMLSchema#string